You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Prognostic value of O‐6‐methylguanine–DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis
|
|---|---|
| Published in |
Neuropathology & Applied Neurobiology, June 2017
|
| DOI | 10.1111/nan.12415 |
| Pubmed ID | |
| Authors |
R. H. Dahlrot, J. Dowsett, S. Fosmark, A. Malmström, R. Henriksson, H. Boldt, K. de Stricker, M. D. Sørensen, H. S. Poulsen, M. Lysiak, P. Söderkvist, J. Rosell, S. Hansen, B. W. Kristensen |
| Abstract |
It is important to predict response to treatment with temozolomide (TMZ) in glioblastoma (GBM) patients. Both MGMT protein expression and MGMT promoter methylation have been reported to predict the response to TMZ. We investigated the prognostic value of quantified MGMT protein levels in tumour cells and the prognostic importance of combining information of MGMT protein level and MGMT promoter methylations status. MGMT protein expression was quantified in tumour cells in 171 GBMs from the population-based Region of Southern Denmark (RSD)-cohort using a double immunofluorescence approach. Pyrosequencing was performed in 157 patients. For validation we used GBM-patients from a Nordic Study (NS) investigating the effect of radiotherapy and different TMZ schedules. When divided at the median, patients with low expression of MGMT protein (AF-low) had the best prognosis (HR 1.5, P = 0.01). Similar results were observed in the subgroup of patients receiving the Stupp regimen (HR 2.0, P = 0.001). In the NS-cohort a trend towards superior survival (HR 1.6, P = 0.08) was seen in patients with AF-low. Including MGMT promoter methylation status, we found for both cohorts that patients with methylated MGMT promoter and AF-low had the best outcome; median OS 23.1 and 20.0 months, respectively. Our data indicate that MGMT protein expression in tumour cells has an independent prognostic significance. Exclusion of non-tumour cells contributed to a more exact analysis of tumour-specific MGMT protein expression. This should be incorporated in future studies evaluating MGMT status before potential integration into clinical practice. This article is protected by copyright. All rights reserved. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 17% |
| Unknown | 5 | 83% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 50% |
| Scientists | 1 | 17% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
| Science communicators (journalists, bloggers, editors) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 18% |
| Student > Bachelor | 5 | 18% |
| Other | 2 | 7% |
| Researcher | 2 | 7% |
| Student > Postgraduate | 2 | 7% |
| Other | 4 | 14% |
| Unknown | 8 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 36% |
| Biochemistry, Genetics and Molecular Biology | 3 | 11% |
| Neuroscience | 2 | 7% |
| Computer Science | 1 | 4% |
| Agricultural and Biological Sciences | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 11 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2019.
All research outputs
#14,984,227
of 25,477,125 outputs
Outputs from Neuropathology & Applied Neurobiology
#809
of 1,173 outputs
Outputs of similar age
#167,300
of 328,611 outputs
Outputs of similar age from Neuropathology & Applied Neurobiology
#19
of 26 outputs
Altmetric has tracked 25,477,125 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,173 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,611 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.